Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Publikationer 2011-2015

2015

Urval av publikationer från 2015 med länkar till abstrakt i pubmed.

CACNA1C polymorphism and altered phosphorylation of tau in bipolar disorder.
Jakobsson J, Pålsson E, Sellgren C, Rydberg F, Ekman A, Zetterberg H, Blennow K, Landén M.
Br J Psychiatry. 2015 Nov 5. pii: bjp.bp.114.159806. [Epub ahead of print]

The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases.
Reijs BL, Teunissen CE, Goncharenko N, Betsou F, Blennow K, Baldeiras I, Brosseron F, Cavedo E, Fladby T, Froelich L, Gabryelewicz T, Gurvit H, Kapaki E, Koson P, Kulic L, Lehmann S, Lewczuk P, Lleó A, Maetzler W, de Mendonça A, Miller AM, Molinuevo JL, Mollenhauer B, Parnetti L, Rot U, Schneider A, Simonsen AH, Tagliavini F, Tsolaki M, Verbeek MM, Verhey FR, Zboch M, Winblad B, Scheltens P, Zetterberg H, Visser PJ.
Front Neurol. 2015 Oct 15;6:216. doi: 10.3389/fneur.2015.00216. eCollection 2015.

Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression.
Zetterberg H, Skillbäck T, Mattsson N, Trojanowski JQ, Portelius E, Shaw LM, Weiner MW,Blennow K; Alzheimer’s Disease Neuroimaging Initiative.
JAMA Neurol. 2015 Nov 2:1-8. doi: 10.1001/jamaneurol.2015.3037. [Epub ahead of print]

Increased CSF biomarkers of angiogenesis in Parkinson disease.
Janelidze S, Lindqvist D, Francardo V, Hall S, Zetterberg H, Blennow K, Adler CH, Beach TG, Serrano GE, van Westen D, Londos E, Cenci MA, Hansson O.
Neurology. 2015 Oct 28. pii: 10.1212/WNL.0000000000002151. [Epub ahead of print]

Assessing the commutability of reference material formats for the harmonization of amyloid beta measurements.
Bjerke M, Andreasson U, Kuhlmann J, Portelius E, Pannee J, Lewczuk P, Umek RM, Vanmechelen E, Vanderstichele H, Stoops E, Lewis J, Vandijck M, Kostanjevecki V, Jeromin A, Salamone SJ, Schmidt O, Matzen A, Madin K, Eichenlaub U, Bittner T, Shaw LM, Zegers I, Zetterberg H, BlennowK.
Clin Chem Lab Med. 2015 Oct 23. pii: /j/cclm.ahead-of-print/cclm-2015-0733/cclm-2015-0733.xml. doi: 10.1515/cclm-2015-0733. [Epub ahead of print]

Cerebrospinal Fluid Fatty Acid-Binding Protein 3 is Related to Dementia Development in a Population-Based Sample of Older Adult Women Followed for 8 Years.
Bjerke M, Kern S, Blennow K, Zetterberg H, Waern M, Börjesson-Hanson A, Östling S, Kern J, Skoog I.
J Alzheimers Dis. 2015 Oct 15. [Epub ahead of print]

The past and the future of Alzheimer's disease CSF biomarkers-a journey toward validated biochemical tests covering the whole spectrum of molecular events.
Blennow K, Zetterberg H.
Front Neurosci. 2015 Sep 29;9:345. doi: 10.3389/fnins.2015.00345. eCollection 2015. Review.

The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.
Cavedo E, Lista S, Khachaturian Z, Aisen P, Amouyel P, Herholz K, Jack CR Jr, Sperling R, Cummings J, Blennow K, O'Bryant S, Frisoni GB, Khachaturian A, Kivipelto M, Klunk W, Broich K, Andrieu S, de Schotten MT, Mangin JF, Lammertsma AA, Johnson K, Teipel S, Drzezga A, Bokde A, Colliot O, Bakardjian H, Zetterberg H, Dubois B, Vellas B, Schneider LS, Hampel H.

Cerebrospinal fluid substance P concentrations are elevated in patients with Alzheimer's disease.
Johansson P, Almqvist EG, Wallin A, Johansson JO, Andreasson U, Blennow K, Zetterberg H, Svensson J.
Neurosci Lett. 2015 Oct 8;609:58-62. doi: 10.1016/j.neulet.2015.10.006. [Epub ahead of print]

Greater Specificity for Cerebrospinal Fluid P-tau231 over P-tau181 in the Differentiation of Healthy Controls from Alzheimer's Disease.
Spiegel J, Pirraglia E, Osorio RS, Glodzik L, Li Y, Tsui W, Saint Louis LA, Randall C, Butler T, Xu J, Zinkowski RP, Zetterberg H, Fortea J, Fossati S, Wisniewski T, Davies P, Blennow K, de Leon MJ.

Dissecting IWG-2 typical and atypical Alzheimer's disease: insights from cerebrospinal fluid analysis.
Paterson RW, Toombs J, Slattery CF, Nicholas JM, Andreasson U, Magdalinou NK, Blennow K, Warren JD, Mummery CJ, Rossor MN, Lunn MP, Crutch SJ, Fox NC, Zetterberg H, Schott JM.
J Neurol. 2015 Sep 26. [Epub ahead of print]

Increased Cerebrospinal Fluid Level of Insulin-like Growth Factor-II in Male Patients with Alzheimer's Disease.
Åberg D, Johansson P, Isgaard J, Wallin A, Johansson JO, Andreasson U, Blennow K, ZetterbergH, Åberg ND, Svensson J.
J Alzheimers Dis. 2015 Oct 1;48(3):637-46. doi: 10.3233/JAD-150351.

Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline.
Lista S, Molinuevo JL, Cavedo E, Rami L, Amouyel P, Teipel SJ, Garaci F, Toschi N, Habert MO,Blennow K, Zetterberg H, O'Bryant SE, Johnson L, Galluzzi S, Bokde AL, Broich K, Herholz K, Bakardjian H, Dubois B, Jessen F, Carrillo MC, Aisen PS, Hampel H.
J Alzheimers Dis. 2015 Sep 24;48 Suppl 1:S171-91. doi: 10.3233/JAD-150202.

Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease?
Travassos M, Santana I, Baldeiras I, Tsolaki M, Gkatzima O, Sermin G, Yener GG, Simonsen A, Hasselbalch SG, Kapaki E, Mara B, Cunha RA, Agostinho P, Blennow K, Zetterberg H, Mendes VM, Manadas B, de Mendon A.
J Alzheimers Dis. 2015 Aug 11;47(4):1069-78. doi: 10.3233/JAD-150374.

Case Report of Complex Amyotrophic Lateral Sclerosis with Cognitive Impairment and Cortical Amyloid Deposition.
Farid K, Carter SF, Rodriguez-Vieitez E, Almkvist O, Andersen P, Wall A, Blennow K, Portelius E,Zetterberg H, Nordberg A.
J Alzheimers Dis. 2015 Aug 3;47(3):661-7. doi: 10.3233/JAD-141965.

Biomarkers in Sporadic and Familial Alzheimer's Disease.
Lista S, O'Bryant SE, Blennow K, Dubois B, Hugon J, Zetterberg H, Hampel H.
J Alzheimers Dis. 2015 Jul 24;47(2):291-317. doi: 10.3233/JAD-143006.

Apolipoprotein E polymorphism in aneurysmal subarachnoid haemorrhage in West Sweden.
Csajbok LZ, Nylén K, Öst M, Blennow K, Zetterberg H, Nellgård P, Nellgård B.
Acta Neurol Scand. 2015 Sep 16. doi: 10.1111/ane.12487. [Epub ahead of print]

Cerebrospinal fluid neurogranin: relation to cognition and neurodegeneration in Alzheimer's disease.
Portelius E, Zetterberg H, Skillbäck T, Törnqvist U, Andreasson U, Trojanowski JQ, Weiner MW, Shaw LM, Mattsson N, Blennow K; Alzheimer’s Disease Neuroimaging Initiative.
Brain. 2015 Nov;138(Pt 11):3373-85. doi: 10.1093/brain/awv267. Epub 2015 Sep 15.

Neurogranin Levels in Cerebrospinal Fluid: A New Addition to the Alzheimer Disease Diagnostic Toolbox.
Zetterberg H, Blennow K.
JAMA Neurol. 2015 Nov 1;72(11):1237-1238. doi: 10.1001/jamaneurol.2015.2075. No abstract available.

Performance and complications of lumbar puncture in memory clinics: Results of the multicenter lumbar puncture feasibility study.
Duits FH, Martinez-Lage P, Paquet C, Engelborghs S, Lleó A, Hausner L, Molinuevo JL, Stomrud E, Farotti L, Ramakers IH, Tsolaki M, Skarsgård C, Åstrand R, Wallin A, Vyhnalek M, Holmber-Clausen M, Forlenza OV, Ghezzi L, Ingelsson M, Hoff EI, Roks G, de Mendonça A, Papma JM, Izagirre A, Taga M, Struyfs H, Alcolea DA, Frölich L, Balasa M, Minthon L, Twisk JW, Persson S, Zetterberg H, van der Flier WM, Teunissen CE, Scheltens P, Blennow K.
Alzheimers Dement. 2015 Sep 11. pii: S1552-5260(15)02702-8. doi: 10.1016/j.jalz.2015.08.003. [Epub ahead of print]

 

Detailed comparison of amyloid PET and CSF biomarkers for identifying early Alzheimer disease.
Palmqvist S, Zetterberg H, Mattsson N, Johansson P; Alzheimer's Disease Neuroimaging Initiative, Minthon L, Blennow K, Olsson M; Swedish BioFINDER study group, Hansson O.
Neurology. 2015 Oct 6;85(14):1240-9. doi: 10.1212/WNL.0000000000001991. Epub 2015 Sep 9.

A Practical Guide to Immunoassay Method Validation.
Andreasson U, Perret-Liaudet A, van Waalwijk van Doorn LJ, Blennow K, Chiasserini D, Engelborghs S, Fladby T, Genc S, Kruse N, Kuiperij HB, Kulic L, Lewczuk P, Mollenhauer B, Mroczko B, Parnetti L, Vanmechelen E, Verbeek MM, Winblad B, Zetterberg H, Koel-Simmelink M, Teunissen CE.
Front Neurol. 2015 Aug 19;6:179. doi: 10.3389/fneur.2015.00179. eCollection 2015.

Protective properties of lysozyme on β-amyloid pathology: implications for Alzheimer disease.
Helmfors L, Boman A, Civitelli L, Nath S, Sandin L, Janefjord C, McCann H, Zetterberg H, BlennowK, Halliday G, Brorsson AC, Kågedal K.
Neurobiol Dis. 2015 Sep 1;83:122-133. doi: 10.1016/j.nbd.2015.08.024. [Epub ahead of print]

Impact of cerebrospinal fluid matrix on the detection of Alzheimer's disease with Aβ42 and influence of disease on the total-Aβ42/Aβ40 ratio.
Slemmon JR, Shapiro A, Mercken M, Streffer J, Romano G, Andreasen N, Zetterberg H, BlennowK.
J Neurochem. 2015 Sep 1. doi: 10.1111/jnc.13297. [Epub ahead of print]

Cerebrospinal Fluid Patterns and the Risk of Future Dementia in Early, Incident Parkinson Disease.
Bäckström DC, Eriksson Domellöf M, Linder J, Olsson B, Öhrfelt A, Trupp M, Zetterberg H,Blennow K, Forsgren L.
JAMA Neurol. 2015 Oct 1;72(10):1175-82. doi: 10.1001/jamaneurol.2015.1449.

The relationship between CSF tau markers, hippocampal volume and delayed primacy performance in cognitively intact elderly individuals.
Bruno D, Grothe MJ, Nierenberg J, Teipel SJ, Zetterberg H, Blennow K, Pomara N.
Alzheimers Dement (Amst). 2015 Mar 1;1(1):81-86.

Alzheimer's disease cerebrospinal fluid biomarker in cognitively normal subjects.
Toledo JB, Zetterberg H, van Harten AC, Glodzik L, Martinez-Lage P, Bocchio-Chiavetto L, Rami L, Hansson O, Sperling R, Engelborghs S, Osorio RS, Vanderstichele H, Vandijck M, Hampel H, Teipl S, Moghekar A, Albert M, Hu WT, Monge Argilés JA, Gorostidi A, Teunissen CE, De Deyn PP, Hyman BT, Molinuevo JL, Frisoni GB, Linazasoro G, de Leon MJ, van der Flier WM, Scheltens P,Blennow K, Shaw LM, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.
Brain. 2015 Sep;138(Pt 9):2701-15. doi: 10.1093/brain/awv199. Epub 2015 Jul 27.

Alzheimer's disease-subcortical vascular disease spectrum in a hospital-based setting: overview of results from the Gothenburg MCI and dementia studies.
Wallin A, Nordlund A, Jonsson M, Blennow K, Zetterberg H, Öhrfelt A, Stålhammar J, Eckerström M, Carlsson M, Olsson E, Göthlin M, Svensson J, Rolstad S, Eckerström C, Bjerke M.
J Cereb Blood Flow Metab. 2015 Jul 29. doi: 10.1038/jcbfm.2015.148. [Epub ahead of print] Review.

Round robin test on quantification of amyloid-β 1-42 in cerebrospinal fluid by mass spectrometry.
Pannee J, Gobom J, Shaw LM, Korecka M, Chambers EE, Lame M, Jenkins R, Mylott W, Carrillo MC, Zegers I, Zetterberg H, Blennow K, Portelius E.
Alzheimers Dement. 2015 Jul 21. pii: S1552-5260(15)02127-5. doi: 10.1016/j.jalz.2015.06.1890. [Epub ahead of print]

Clearance systems in the brain-implications for Alzheimer disease.
Tarasoff-Conway JM, Carare RO, Osorio RS, Glodzik L, Butler T, Fieremans E, Axel L, Rusinek H, Nicholson C, Zlokovic BV, Frangione B, Blennow K, Ménard J, Zetterberg H, Wisniewski T, de Leon MJ.
Nat Rev Neurol. 2015 Aug;11(8):457-70. doi: 10.1038/nrneurol.2015.119. Epub 2015 Jul 21. Review.

The Alzheimer's Disease Neuroimaging Initiative 2 Biomarker Core: A review of progress and plans.
Kang JH, Korecka M, Figurski MJ, Toledo JB, Blennow K, Zetterberg H, Waligorska T, Brylska M, Fields L, Shah N, Soares H, Dean RA, Vanderstichele H, Petersen RC, Aisen PS, Saykin AJ, Weiner MW, Trojanowski JQ, Shaw LM; Alzheimer's Disease Neuroimaging Initiative.
Alzheimers Dement. 2015 Jul;11(7):772-91. doi: 10.1016/j.jalz.2015.05.003. Review.

The Gothenburg MCI study: design and distribution of Alzheimer's disease and subcortical vascular disease diagnoses from baseline to 6-year follow-up.
Wallin A, Nordlund A, Jonsson M, Lind K, Edman Å, Göthlin M, Stålhammar J, Eckerström M, Kern S, Börjesson-Hanson A, Carlsson M, Olsson E, Zetterberg H, Blennow K, Svensson J, Öhrfelt A, Bjerke M, Rolstad S, Eckerström C.
J Cereb Blood Flow Metab. 2015 Jul 15. doi: 10.1038/jcbfm.2015.147. [Epub ahead of print] Review.

Pre-analytical and analytical factors influencing Alzheimer's disease cerebrospinal fluid biomarker variability.
Fourier A, Portelius E, Zetterberg H, Blennow K, Quadrio I, Perret-Liaudet A.
Clin Chim Acta. 2015 Sep 20;449:9-15. doi: 10.1016/j.cca.2015.05.024. Epub 2015 Jun 30. Review.

Characterization of the postsynaptic protein neurogranin in paired cerebrospinal fluid and plasma samples from Alzheimer's disease patients and healthy controls.
Kvartsberg H, Portelius E, Andreasson U, Brinkmalm G, Hellwig K, Lelental N, Kornhuber J, Hansson O, Minthon L, Spitzer P, Maler JM, Zetterberg H, Blennow K, Lewczuk P.
Alzheimers Res Ther. 2015 Jul 1;7(1):40. doi: 10.1186/s13195-015-0124-3. eCollection 2015.

Cerebrospinal fluid tau and amyloid-β1-42 in patients with dementia.
Skillbäck T, Farahmand BY, Rosén C, Mattsson N, Nägga K, Kilander L, Religa D, Wimo A, Winblad B, Schott JM, Blennow K, Eriksdotter M, Zetterberg H.
Brain. 2015 Sep;138(Pt 9):2716-31. doi: 10.1093/brain/awv181. Epub 2015 Jun 30.

Validation of a quantitative cerebrospinal fluid alpha-synuclein assay in a European-wide interlaboratory study.
Kruse N, Persson S, Alcolea D, Bahl JM, Baldeiras I, Capello E, Chiasserini D, Bocchio Chiavetto L, Emersic A, Engelborghs S, Eren E, Fladby T, Frisoni G, García-Ayllón MS, Genc S, Gkatzima O, Heegaard NH, Janeiro AM, Kováčech B, Kuiperij HB, Leitão MJ, Lleó A, Martins M, Matos M, Mollergard HM, Nobili F, Öhrfelt A, Parnetti L, de Oliveira CR, Rot U, Sáez-Valero J, Struyfs H, Tanassi JT, Taylor P, Tsolaki M, Vanmechelen E, Verbeek MM, Zilka N, Blennow K, Zetterberg H, Mollenhauer B.
Neurobiol Aging. 2015 Sep;36(9):2587-96. doi: 10.1016/j.neurobiolaging.2015.05.003. Epub 2015 May 15.

C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease.
De Vos A, Jacobs D, Struyfs H, Fransen E, Andersson K, Portelius E, Andreasson U, De Surgeloose D, Hernalsteen D, Sleegers K, Robberecht C, Van Broeckhoven C, Zetterberg H, Blennow K, Engelborghs S, Vanmechelen E.
Alzheimers Dement. 2015 Jun 16. pii: S1552-5260(15)00181-8. doi: 10.1016/j.jalz.2015.05.012. [Epub ahead of print]

Benchmarking biomarker-based criteria for Alzheimer's disease: Data from the Swedish Dementia Registry, SveDem.
Rosén C, Farahmand B, Skillbäck T, Nägga K, Mattsson N, Kilander L, Religa D, Wimo A, BlennowK, Winblad B, Zetterberg H, Eriksdotter M.
Alzheimers Dement. 2015 Jun 13. pii: S1552-5260(15)00185-5. doi: 10.1016/j.jalz.2015.04.007. [Epub ahead of print]

CSF neuroinflammatory biomarkers in bipolar disorder are associated with cognitive impairment.
Rolstad S, Jakobsson J, Sellgren C, Isgren A, Ekman CJ, Bjerke M, Blennow K, Zetterberg H, Pålsson E, Landén M.
Eur Neuropsychopharmacol. 2015 Aug;25(8):1091-8. doi: 10.1016/j.euroneuro.2015.04.023. Epub 2015 May 5.
 

Monocyte and microglial activation in patients with mood-stabilized bipolar disorder.
Jakobsson J, Bjerke M, Sahebi S, Isgren A, Ekman CJ, Sellgren C, Olsson B, Zetterberg H, Blennow K, Pålsson E, Landén M.
J Psychiatry Neurosci. 2015 Mar 17

Understanding Biomarkers of Neurodegeneration: Ultrasensitive detection techniques pave the way for mechanistic understanding.
Blennow K, Zetterberg H.
Nat Med. 2015 Mar 5

Glial and neuronal markers in cerebrospinal fluid predict progression in multiple sclerosis.
Martínez MA, Olsson B, Bau L, Matas E, Calvo ÁC, Andreasson U, Blennow K, Romero-Pinel L, Martínez-Yélamos S, Zetterberg H.
Mult Scler. 2015 Mar 2 [Epub ahead of print]

A 9-Year Prospective Population-Based Study on the Association Between the APOE*E4 Allele and Late-Life Depression in Sweden.
Skoog I, Waern M, Duberstein P, Blennow K, Zetterberg H, Börjesson-Hanson A, Östling S, Guo X, Kern J, Gustafson D, Gudmundsson P, Marlow T, Kern S.
Biol Psychiatry. 2015 Jan 29.[Epub ahead of print]

Alzheimer's disease - Recent biomarker developments in relation to updated diagnostic criteria.
Höglund K, Fourier A, Perret-Liaudet A, Zetterberg H, Blennow K, Portelius E.
Clin Chim Acta. 2015 Feb 7. [Epub ahead of print]

Fluid markers of traumatic brain injury.
Zetterberg H, Blennow K.
Mol Cell Neurosci. 2015 Feb 3.[Epub ahead of print]

Serum tau fragments predict return to play in concussed professional ice hockey players.
Shahim P, Linemann T, Inekci D, Karsdal MA, Blennow K, Tegner Y, Zetterberg H, Henriksen K.
J Neurotrauma. 2015 Jan 26. [Epub ahead of print]

Explorative and targeted neuroproteomics in Alzheimer's disease.
Brinkmalm A, Portelius E, Öhrfelt A, Brinkmalm G, Andreasson U, Gobom J, Blennow K, Zetterberg H.
Biochim Biophys Acta. 2015 Jan 22

A study on the specificity of the association between hippocampal volume and delayed primacy performance in cognitively intact elderly individuals.
Bruno D, Grothe MJ, Nierenberg J, Zetterberg H, Blennow K, Teipel SJ, Pomara N.
Neuropsychologia. 2015 Mar

The distribution of apolipoprotein E genotype over the adult lifespan and in relation to country of birth.
Kern S, Mehlig K, Kern J, Zetterberg H, Thelle D, Skoog I, Lissner L, Blennow K, Börjesson-Hanson A.
Am J Epidemiol. 2015 Feb 1

Brain amyloid-Beta fragment signatures in pathological ageing and Alzheimer's disease by hybrid immunoprecipitation mass spectrometry.
Portelius E, Lashley T, Westerlund A, Persson R, Fox NC, Blennow K, Revesz T, Zetterberg H.
Neurodegener Dis. 2015;15(1):50-7. doi: 10.1159/000369465. Epub 2015 Jan 13.

A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes.
Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K, Bhatia K, Morris HR, Giunti P, Warner TT, de Silva R, Lees AJ, Zetterberg H.
J Neurol Neurosurg Psychiatry. 2015 Jan 14.

Laboratory testing for lyme neuroborreliosis.
Lautner R, Zetterberg H, Blennow K.
JAMA Neurol. 2015 Jan

Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease.
Mattsson N, Insel PS, Donohue M, Landau S, Jagust WJ, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner MW; Alzheimer's Disease Neuroimaging Initiative*.
Brain. 2015 Mar

Comment on "An antidepressant decreases CSF Aβ production in healthy individuals and in transgenic AD mice".
Emilsson JF, Andreasson U, Blennow K, Eriksson E, Zetterberg H.
Sci Transl Med. 2014 Dec 24

Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.
Kvartsberg H, Duits FH, Ingelsson M, Andreasen N, Öhrfelt A, Andersson K, Brinkmalm G, Lannfelt L, Minthon L, Hansson O, Andreasson U, Teunissen CE, Scheltens P, Van der Flier WM, Zetterberg H, Portelius E, Blennow K.
Alzheimers Dement. 2014 Dec 19

Rarity of the Alzheimer Disease-Protective APP A673T Variant in the United States.
Wang LS, Naj AC, Graham RR, Crane PK, Kunkle BW, Cruchaga C, Murcia JD, Cannon-Albright L, Baldwin CT, Zetterberg H, Blennow K, Kukull WA, Faber KM, Schupf N, Norton MC, Tschanz JT, Munger RG, Corcoran CD, Rogaeva E, Lin CF, Dombroski BA, Cantwell LB, Partch A, Valladares O, Hakonarson H, St George-Hyslop P, Green RC, Goate AM, Foroud TM, Carney RM, Larson EB, Behrens TW, Kauwe JS, Haines JL, Farrer LA, Pericak-Vance MA, Mayeux R, Schellenberg GD; National Institute on Aging–Late-Onset Alzheimer’s Disease (NIA-LOAD) Family Study; Alzheimer’s Disease Genetics Consortium, Albert MS, Albin RL, Apostolova LG, Arnold SE, Barber R, Barmada MM, Barnes LL, Beach TG, Becker JT, Beecham GW, Beekly D, Bennett DA, Bigio EH, Bird TD, Blacker D, Boeve BF, Bowen JD, Boxer A, Burke JR, Buxbaum JD, Cairns NJ, Cao C, Carlson CS, Carroll SL, Chui HC, Clark DG, Cribbs DH, Crocco EA, DeCarli C, DeKosky ST, Demirci FY, Dick M, Dickson DW, Duara R, Ertekin-Taner N, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Glass JD, Graff-Radford NR, Growdon JH, Hamilton RL, Hamilton-Nelson KL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jarvik GP, Jicha GA, Jin LW, Jun G, Kamboh MI, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Kramer JH, Kramer P, LaFerla FM, Lah JJ, Leverenz JB, Levey AI, Li G, Lieberman AP, Lopez OL, Lunetta KL, Lyketsos CG, Mack WJ, Marson DC, Martin ER, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam MM, Miller BL, Miller CA, Miller JW, Montine TJ, Morris JC, Murrell JR, Olichney JM, Parisi JE, Perry W, Peskind E, Petersen RC, Pierce A, Poon WW, Potter H, Quinn JF, Raj A, Raskind M, Reiman EM, Reisberg B, Reitz C, Ringman JM, Roberson ED, Rosen HJ, Rosenberg RN, Sano M, Saykin AJ, Schneider JA, Schneider LS, Seeley WW, Smith AG, Sonnen JA, Spina S, Stern RA, Tanzi RE, Thornton-Wells TA, Trojanowski JQ, Troncoso JC, Tsuang DW, Van Deerlin VM, Van Eldik LJ, Vardarajan BN, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Wishnek S, Woltjer RL, Wright CB, Younkin SG, Yu CE, Yu L.
JAMA Neurol. 2015 Feb

Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases.
Lleó A, Cavedo E, Parnetti L, Vanderstichele H, Herukka SK, Andreasen N, Ghidoni R, Lewczuk P, Jeromin A, Winblad B, Tsolaki M, Mroczko B, Visser PJ, Santana I, Svenningsson P, Blennow K, Aarsland D, Molinuevo JL, Zetterberg H, Mollenhauer B.
Nat Rev Neurol. 2015 Jan

Cerebrovascular Biomarker Profile Is Related to White Matter Disease and Ventricular Dilation in a LADIS Substudy.
Bjerke M, Jonsson M, Nordlund A, Eckerström C, Blennow K, Zetterberg H, Pantoni L, Inzitari D, Schmidt R, Wallin A.
Dement Geriatr Cogn Dis Extra. 2014 Oct

An integrated workflow for multiplex CSF proteomics and peptidomics-identification of candidate cerebrospinal fluid biomarkers of Alzheimer's disease.
Hölttä M, Minthon L, Hansson O, Holmén-Larsson J, Pike I, Ward M, Kuhn K, Rüetschi U, Zetterberg H, Blennow K, Gobom J.
J Proteome Res. 2015 Feb

Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment.
Isgren A, Jakobsson J, Pålsson E, Ekman CJ, Johansson AG, Sellgren C, Blennow K, Zetterberg H, Landén M.
Brain Behav Immun. 2015 Jan

Genetic Variants of GSK3B are Associated with Biomarkers for Alzheimer's Disease and Cognitive Function.
Kettunen P, Larsson S, Holmgren S, Olsson S, Minthon L, Zetterberg H, Blennow K, Nilsson S, Sjölander A.
J Alzheimers Dis. 2015 Jan

2014

Publikationer från 2014 med länkar till abstrakt i pubmed.

Serum SNTF Increases in Concussed Professional Ice Hockey Players and Relates to the Severity of Post-Concussion Symptoms.
Siman R, Shahim P, Tegner Y, Blennow K, Zetterberg H, Smith DH Dr.
J Neurotrauma. 2014 Nov 24. [Epub ahead of print]

SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease.
Brinkmalm A, Brinkmalm G, Honer WG, Frölich L, Hausner L, Minthon L, Hansson O, Wallin A, Zetterberg H, Blennow K, Öhrfelt A.
Mol Neurodegener. 2014 Nov

β-site amyloid precursor protein-cleaving enzyme 1(BACE1) inhibitor treatment induces Aβ5-X peptides through alternative amyloid precursor protein cleavage.
Portelius E, Dean RA, Andreasson U, Mattsson N, Westerlund A, Olsson M, Demattos RB, Racke MM, Zetterberg H, May PC, Blennow K.
Alzheimers Res Ther. 2014 Nov

Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease.
Mattsson N, Insel PS, Landau S, Jagust W, Donohue M, Shaw LM, Trojanowski JQ, Zetterberg H, Blennow K, Weiner M; Alzheimer's Disease Neuroimaging Initiativea.
Ann Clin Transl Neurol. 2014 Aug

CSF neurofilament light differs in neurodegenerative diseases and predicts severity and survival.
Skillbäck T, Farahmand B, Bartlett JW, Rosén C, Mattsson N, Nägga K, Kilander L, Religa D, Wimo A, Winblad B, Rosengren L, Schott JM, Blennow K, Eriksdotter M, Zetterberg H.
Neurology. 2014 Nov

Increased Levels of Chitotriosidase and YKL-40 in Cerebrospinal Fluid from Patients with Alzheimer's Disease.
Rosén C, Andersson CH, Andreasson U, Molinuevo JL, Bjerke M, Rami L, Lladó A, Blennow K, Zetterberg H.
Dement Geriatr Cogn Dis Extra. 2014 Jul

CSF in Alzheimer's disease.
Zetterberg H, Lautner R, Skillbäck T, Rosén C, Shahim P, Mattsson N, Blennow K.
Adv Clin Chem. 2014;65:143-72. Review.
 

Preclinical Cerebrospinal Fluid and Volumetric Magnetic Resonance Imaging Biomarkers in Swedish Familial Alzheimer's Disease.
Thordardottir S, Ståhlbom AK, Ferreira D, Almkvist O, Westman E, Zetterberg H, Eriksdotter M, Blennow K, Graff C.
J Alzheimers Dis. 2014 Sep 2. [Epub ahead of print]

Apolipoprotein E Genotype and the Diagnostic Accuracy of Cerebrospinal Fluid Biomarkers for Alzheimer Disease.
Lautner R, Palmqvist S, Mattsson N, Andreasson U, Wallin A, Pålsson E, Jakobsson J, Herukka SK, Owenius R, Olsson B, Hampel H, Rujescu D, Ewers M, Landén M, Minthon L, Blennow K, Zetterberg H, Hansson O; for the Alzheimer’s Disease Neuroimaging Initiative.
JAMA Psychiatry. 2014 Aug 27. doi: 10.1001/jamapsychiatry.2014.1060. [Epub ahead of print]

Accuracy of Brain Amyloid Detection in Clinical Practice Using Cerebrospinal Fluid β-Amyloid 42: A Cross-Validation Study Against Amyloid Positron Emission Tomography.
Palmqvist S, Zetterberg H, Blennow K, Vestberg S, Andreasson U, Brooks DJ, Owenius R, Hägerström D, Wollmer P, Minthon L, Hansson O.
JAMA Neurol. 2014 Aug 25. doi: 10.1001/jamaneurol.2014.1358. [Epub ahead of print]

Tau, s-100 calcium-binding protein B, and neuron-specific enolase as biomarkers of concussion-reply.
Shahim P, Blennow K, Zetterberg H.
JAMA Neurol. 2014 Jul 1;71(7):926-7. doi: 10.1001/jamaneurol.2014.1160. No abstract available.

Exploring Alzheimer Molecular Pathology in Down's Syndrome Cerebrospinal Fluid.
Portelius E, Soininen H, Andreasson U, Zetterberg H, Persson R, Karlsson G, Blennow K, Herukka SK, Mattsson N.
Neurodegener Dis. 2014;14(2):98-106. doi: 10.1159/000358800. Epub 2014 Jun 27.

Levels of cerebrospinal fluid α-synuclein oligomers are increased in Parkinson's disease with dementia and dementia with Lewy bodies compared to Alzheimer's disease.
Hansson O, Hall S, Ohrfelt A, Zetterberg H, Blennow K, Minthon L, Nägga K, Londos E, Varghese S, Majbour NK, Al-Hayani A, El-Agnaf OM.
Alzheimers Res Ther. 2014 May 7;6(3):25. doi: 10.1186/alzrt255. eCollection 2014.

Targeting synaptic pathology with a novel affinity mass spectrometry approach.
Brinkmalm A, Brinkmalm G, Honer WG, Moreno JA, Jakobsson J, Mallucci GR, Zetterberg H, Blennow K, Ohrfelt A.
Mol Cell Proteomics. 2014 Jun 27. pii: mcp.M114.040113. [Epub ahead of print]

Cerebrospinal fluid sphingolipids, β-amyloid, and tau in adults at risk for Alzheimer's disease.
Mielke MM, Haughey NJ, Bandaru VV, Zetterberg H, Blennow K, Andreasson U, Johnson SC, Gleason CE, Blazel HM, Puglielli L, Sager MA, Asthana S, Carlsson CM.
Neurobiol Aging. 2014 May 27. pii: S0197-4580(14)00382-0. doi: 10.1016/j.neurobiolaging.2014.05.019. [Epub ahead of print]

Reporting standards for studies of diagnostic test accuracy in dementia: The STARDdem Initiative.
Noel-Storr AH, McCleery JM, Richard E, Ritchie CW, Flicker L, Cullum SJ, Davis D, Quinn TJ, Hyde C, Rutjes AW, Smailagic N, Marcus S, Black S, Blennow K, Brayne C, Fiorivanti M, Johnson JK, Köpke S, Schneider LS, Simmons A, Mattsson N, Zetterberg H, Bossuyt PM, Wilcock G, McShane R.
Neurology. 2014 Jul 22;83(4):364-73. doi: 10.1212/WNL.0000000000000621. Epub 2014 Jun 18.

Neurological assessment and its relationship to CSF biomarkers in amateur boxers.
Neselius S, Brisby H, Marcusson J, Zetterberg H, Blennow K, Karlsson T.
PLoS One. 2014 Jun 18;9(6):e99870. doi: 10.1371/journal.pone.0099870. eCollection 2014.
PMID: 24941067 [PubMed - in process] Free PMC Article
Related citations
Select item 24932109

Neuronal and glia-related biomarkers in cerebrospinal fluid of patients with acute ischemic stroke.
Hjalmarsson C, Bjerke M, Andersson B, Blennow K, Zetterberg H, Aberg ND, Olsson B, Eckerström C, Bokemark L, Wallin A.
J Cent Nerv Syst Dis. 2014 May 19;6:51-8. doi: 10.4137/JCNSD.S13821. eCollection 2014.

Metabolite and Peptide Levels in Plasma and CSF Differentiating Healthy Controls from Patients with Newly Diagnosed Parkinson's Disease.
Trupp M, Jonsson P, Ohrfelt A, Zetterberg H, Obudulu O, Malm L, Wuolikainen A, Linder J, Moritz T, Blennow K, Antti H, Forsgren L.
J Parkinsons Dis. 2014 Jan 1;4(3):549-60. doi: 10.3233/JPD-140389.

Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample.
Kern S, Skoog I, Börjesson-Hanson A, Blennow K, Zetterberg H, Ostling S, Kern J, Gudmundsson P, Marlow T, Rosengren L, Waern M.
Brain Behav Immun. 2014 Oct;41:55-8. doi: 10.1016/j.bbi.2014.05.006. Epub 2014 May 20.

Mass spectrometry-based candidate reference measurement procedure for quantification of amyloid-β in cerebrospinal fluid.
Leinenbach A, Pannee J, Dülffer T, Huber A, Bittner T, Andreasson U, Gobom J, Zetterberg H, Kobold U, Portelius E, Blennow K; IFCC Scientific Division Working Group on CSF proteins.
Clin Chem. 2014 Jul;60(7):987-94. doi: 10.1373/clinchem.2013.220392. Epub 2014 May 19.

Monitoring concussion in a knocked-out boxer by CSF biomarker analysis.
Neselius S, Brisby H, Granholm F, Zetterberg H, Blennow K.
Knee Surg Sports Traumatol Arthrosc. 2014 May 13. [Epub ahead of print]

Cerebrospinal fluid analysis in Alzheimer's disease: technical issues and future developments.
Lista S, Zetterberg H, Dubois B, Blennow K, Hampel H.
J Neurol. 2014 Jun;261(6):1234-43. doi: 10.1007/s00415-014-7366-z. Epub 2014 May 8.

Neurochemical evidence of potential neurotoxicity after prophylactic cranial irradiation.
Kalm M, Abel E, Wasling P, Nyman J, Hietala MA, Bremell D, Hagberg L, Elam M, Blennow K, Björk-Eriksson T, Zetterberg H.
Int J Radiat Oncol Biol Phys. 2014 Jul 1;89(3):607-14. doi: 10.1016/j.ijrobp.2014.03.019. Epub 2014 May 3.

The amyloid-β degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's disease.
Pannee J, Törnqvist U, Westerlund A, Ingelsson M, Lannfelt L, Brinkmalm G, Persson R, Gobom J, Svensson J, Johansson P, Zetterberg H, Blennow K, Portelius E.
Neurosci Lett. 2014 Jun 24;573:7-12. doi: 10.1016/j.neulet.2014.04.041. Epub 2014 May 4.

CSF Aβ42 predicts early-onset dementia in Parkinson disease.
Alves G, Lange J, Blennow K, Zetterberg H, Andreasson U, Førland MG, Tysnes OB, Larsen JP, Pedersen KF.
Neurology. 2014 May 20;82(20):1784-90. doi: 10.1212/WNL.0000000000000425. Epub 2014 Apr 18.

Blood-cerebrospinal fluid barrier dysfunction in patients with bipolar disorder in relation to antipsychotic treatment.
Zetterberg H, Jakobsson J, Redsäter M, Andreasson U, Pålsson E, Ekman CJ, Sellgren C, Johansson AG, Blennow K, Landén M.
Psychiatry Res. 2014 Jul 30;217(3):143-6. doi: 10.1016/j.psychres.2014.03.045. Epub 2014 Apr 5.

Altered cerebrospinal fluid levels of amyloid β and amyloid precursor-like protein 1 peptides in Down's syndrome.
Portelius E, Hölttä M, Soininen H, Bjerke M, Zetterberg H, Westerlund A, Herukka SK, Blennow K, Mattsson N.
Neuromolecular Med. 2014 Jun;16(2):510-6. doi: 10.1007/s12017-014-8302-1. Epub 2014 Apr 18.

The cerebrospinal fluid "Alzheimer profile": Easily said, but what does it mean?
Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, Zetterberg H, Blennow K, Hansson O, Minthon L, Andreasen N, Marcusson J, Wallin A, Rikkert MO, Tsolaki M, Parnetti L, Herukka SK, Hampel H, De Leon MJ, Schröder J, Aarsland D, Blankenstein MA, Scheltens P, van der Flier WM.
Alzheimers Dement. 2014 Apr 7. pii: S1552-5260(14)00029-6. doi: 10.1016/j.jalz.2013.12.023. [Epub ahead of print]

Elevated concentrations of neurofilament light chain in the cerebrospinal fluid of bipolar disorder patients.
Jakobsson J, Bjerke M, Ekman CJ, Sellgren C, Johansson AG, Zetterberg H, Blennow K, Landén M.
Neuropsychopharmacology. 2014 Sep;39(10):2349-56. doi: 10.1038/npp.2014.81. Epub 2014 Apr 3.

Blood biomarkers for brain injury in concussed professional ice hockey players.
Shahim P, Tegner Y, Wilson DH, Randall J, Skillbäck T, Pazooki D, Kallberg B, Blennow K, Zetterberg H.
JAMA Neurol. 2014 Jun;71(6):684-92.

CSF levels of YKL-40 are increased in MS and replaces with immunosuppressive treatment.
Malmeström C, Axelsson M, Lycke J, Zetterberg H, Blennow K, Olsson B.
J Neuroimmunol. 2014 Apr 15;269(1-2):87-9. doi: 10.1016/j.jneuroim.2014.02.004. Epub 2014 Feb 13.

Diagnostic performance of cerebrospinal fluid total tau and phosphorylated tau in Creutzfeldt-Jakob disease: results from the Swedish Mortality Registry.
Skillbäck T, Rosén C, Asztely F, Mattsson N, Blennow K, Zetterberg H.
JAMA Neurol. 2014 Apr;71(4):476-83. doi: 10.1001/jamaneurol.2013.6455.

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples.
Skillbäck T, Zetterberg H, Blennow K, Mattsson N.
Alzheimers Res Ther. 2013 Oct 14;5(5):47. doi: 10.1186/alzrt212.

The interaction between sleep-disordered breathing and apolipoprotein E genotype on cerebrospinal fluid biomarkers for Alzheimer's disease in cognitively normal elderly individuals.
Osorio RS, Ayappa I, Mantua J, Gumb T, Varga A, Mooney AM, Burschtin OE, Taxin Z, During E, Spector N, Biagioni M, Pirraglia E, Lau H, Zetterberg H, Blennow K, Lu SE, Mosconi L, Glodzik L, Rapoport DM, de Leon MJ.
Neurobiol Aging. 2014 Jun;35(6):1318-24. doi: 10.1016/j.neurobiolaging.2013.12.030. Epub 2013 Dec 27.

Non-neurological surgery and cerebrospinal fluid biomarkers for neuronal and astroglial integrity.
Anckarsäter R, Anckarsäter H, Bromander S, Blennow K, Wass C, Zetterberg H.
J Neural Transm. 2014 Jun;121(6):649-53. doi: 10.1007/s00702-013-1156-0. Epub 2014 Jan 14.

The role of clusterin in amyloid-β-associated neurodegeneration.
Desikan RS, Thompson WK, Holland D, Hess CP, Brewer JB, Zetterberg H, Blennow K, Andreassen OA, McEvoy LK, Hyman BT, Dale AM; Alzheimer’s Disease Neuroimaging Initiative Group.
JAMA Neurol. 2014 Feb;71(2):180-7. doi: 10.1001/jamaneurol.2013.4560.

Imatinib treatment and Aβ42 in humans.
Olsson B, Legros L, Guilhot F, Strömberg K, Smith J, Livesey FJ, Wilson DH, Zetterberg H, Blennow K.
Alzheimers Dement. 2013 Dec 10. pii: S1552-5260(13)02839-2. doi: 10.1016/j.jalz.2013.08.283. [Epub ahead of print]

Cerebrospinal fluid (CSF) 25-hydroxyvitamin D concentration and CSF acetylcholinesterase activity are reduced in patients with Alzheimer's disease.
Johansson P, Almqvist EG, Johansson JO, Mattsson N, Andreasson U, Hansson O, Wallin A, Blennow K, Zetterberg H, Svensson J.
PLoS One. 2013 Nov 29;8(11):e81989. doi: 10.1371/journal.pone.0081989. eCollection 2013.

Automated cerebrospinal fluid cell count--new reference ranges and evaluation of its clinical use in central nervous system infections.
Bremell D, Mattsson N, Wallin F, Henriksson J, Wall M, Blennow K, Zetterberg H, Hagberg L.
Clin Biochem. 2014 Jan;47(1-2):25-30. doi: 10.1016/j.clinbiochem.2013.11.010. Epub 2013 Nov 22.

Perspective on future role of biological markers in clinical therapy trials of Alzheimer's disease: a long-range point of view beyond 2020.
Hampel H, Lista S, Teipel SJ, Garaci F, Nisticò R, Blennow K, Zetterberg H, Bertram L, Duyckaerts C, Bakardjian H, Drzezga A, Colliot O, Epelbaum S, Broich K, Lehéricy S, Brice A, Khachaturian ZS, Aisen PS, Dubois B.
Biochem Pharmacol. 2014 Apr 15;88(4):426-49. doi: 10.1016/j.bcp.2013.11.009. Epub 2013 Nov 22. Review.

Increased CSF levels of phosphorylated neurofilament heavy protein following bout in amateur boxers.
Neselius S, Zetterberg H, Blennow K, Marcusson J, Brisby H.
PLoS One. 2013 Nov 15;8(11):e81249. doi: 10.1371/journal.pone.0081249. eCollection 2013.

Cerebrospinal fluid biomarkers in cardiac arrest survivors.
Rosén C, Rosén H, Andreasson U, Bremell D, Bremler R, Hagberg L, Rosengren L, Blennow K, Zetterberg H.
Resuscitation. 2014 Feb;85(2):227-32. doi: 10.1016/j.resuscitation.2013.10.032. Epub 2013 Nov 11.

2013 

Publikationer från 2013 med länkar till abstrakt i pubmed.

The association between plasma homocysteine and coronary heart disease is modified by the MTHFR 677C>T polymorphism.
Mehlig K, Leander K, de Faire U, Nyberg F, Berg C, Rosengren A, Björck L, Zetterberg H, Blennow K, Tognon G, Torén K, Strandhagen E, Lissner L, Thelle D.
Heart. 2013 Sep 7.


Blood pressure decrease correlates with tau pathology and memory decline in hypertensive elderly.
Glodzik L, Rusinek H, Pirraglia E, McHugh P, Tsui W, Williams S, Cummings M, Li Y, Rich K, Randall C, Mosconi L, Osorio R, Murray J, Zetterberg H, Blennow K, de Leon M. Neurobiol Aging. 2013 Aug 19.


Evaluation of the Cerebrospinal Fluid Amyloid-β1-42/Amyloid-β1-40 Ratio Measured by Alpha-LISA to Distinguish Alzheimer's Disease from Other Dementia Disorders.
Nutu M, Zetterberg H, Londos E, Minthon L, Nägga K, Blennow K, Hansson O, Ohrfelt A.
Dement Geriatr Cogn Disord. 2013


CSF Aβ1-42 combined with neuroimaging biomarkers in the early detection, diagnosis and prediction of Alzheimer's disease.
Lista S, Garaci FG, Ewers M, Teipel S, Zetterberg H, Blennow K, Hampel H. Alzheimers Dement. 2013 Jul 11.

The glial marker YKL-40 is decreased in synucleinopathies.
Olsson B, Constantinescu R, Holmberg B, Andreasen N, Blennow K, Zetterberg H.
Mov Disord. 2013 Jul 11. [Epub ahead of print]

Monitoring of β-Amyloid Dynamics after Human Traumatic Brain Injury.
Marklund N, Farrokhnia N, Hånell A, Vanmechelen E, Enblad P, Zetterberg H, Blennow K, Hillered L.
J Neurotrauma. 2013 Jul 7. [Epub ahead of print]

Cerebrospinal fluid brain injury biomarkers in children: a multicenter study.
Shahim P, Darin N, Andreasson U, Blennow K, Jennions E, Lundgren J, Månsson JE, Naess K, Törnhage CJ, Zetterberg H, Mattsson N.
Pediatr Neurol. 2013 Jul.

Fluid biomarkers in Alzheimer's disease - current concepts.
Rosén C, Hansson O, Blennow K, Zetterberg H.
Mol Neurodegener. 2013 Jun 21

Biomarkers in Amyloid-β Immunotherapy Trials in Alzheimer's Disease.
Blennow K, Hampel H, Zetterberg H.
Neuropsychopharmacology. 2013 Jun 25.

Evaluating amyloid-β oligomers in cerebrospinal fluid as a biomarker for Alzheimer's disease.
Hölttä M, Hansson O, Andreasson U, Hertze J, Minthon L, Nägga K, Andreasen N, Zetterberg H, Blennow K.
PLoS One. 2013 Jun 14

Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid-β changes occur before increases of tau in cerebrospinal fluid.
Braak H, Zetterberg H, Del Tredici K, Blennow K.
Acta Neuropathol. 2013 Jun 12. [Epub ahead of print]

Neurodegenerative and inflammatory biomarkers in cerebrospinal fluid in patients with Cushing's syndrome in remission.
Ragnarsson O, Berglund P, Eder DN, Zetterberg H, Hietala MA, Blennow K, Johannsson G.
Eur J Endocrinol. 2013 Jul 6

Cerebrospinal fluid analyses for the diagnosis of subarachnoid haemorrhage and experience from a Swedish study. What method is preferable when diagnosing a subarachnoid haemorrhage?
Nagy K, Skagervik I, Tumani H, Petzold A, Wick M, Kühn HJ, Uhr M, Regeniter A, Brettschneider J, Otto M, Kraus J, Deisenhammer F, Lautner R, Blennow K, Shaw L, Zetterberg H, Mattsson N.
Clin Chem Lab Med. 2013 May 9

The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease.
Blennow K, Zetterberg H.
Med Clin North Am. 2013 May;97(3):369-76. doi: 10.1016/j.mcna.2012.12.012. Epub 2013 Feb 1. Review.

CSF biomarker variability in the Alzheimer's Association quality control program.
Mattsson N, Andreasson U, Persson S, Carrillo MC, Collins S, Chalbot S, Cutler N, Dufour-Rainfray D, Fagan AM, Heegaard NH, Robin Hsiung GY, Hyman B, Iqbal K, Lachno DR, Lleó A, Lewczuk P, Molinuevo JL, Parchi P, Regeniter A, Rissman R, Rosenmann H, Sancesario G, Schröder J, Shaw LM, Teunissen CE, Trojanowski JQ, Vanderstichele H, Vandijck M, Verbeek MM, Zetterberg H, Blennow K, Käser SA; Alzheimer's Association QC Program Work Group.
Alzheimers Dement. 2013 May.


Lower CSF interleukin-6 predicts future depression in a population-based sample of older women followed for 17 years.
Kern S, Skoog I, Börjesson-Hanson A, Blennow K, Zetterberg H, Östling S, Kern J, Gudmundsson P, Marlow T, Rosengren L, Waern M.
Brain Behav Immun. 2013 Aug. Epub 2013 Apr 9.

Plasma tau levels in Alzheimer's disease.
Zetterberg H, Wilson D, Andreasson U, Minthon L, Blennow K, Randall J, Hansson O.
Alzheimers Res Ther. 2013 Mar 28;5(2):9. [Epub ahead of print].

Soluble amyloid precursor protein α and β in CSF in Alzheimer's disease.
Brinkmalm G, Brinkmalm A, Bourgeois P, Persson R, Hansson O, Portelius E, Mercken M, Andreasson U, Parent S, Lipari F, Ohrfelt A, Bjerke M, Minthon L, Zetterberg H, Blennow K, Nutu M.
Brain Res. 2013 Jun 4.Epub 2013 Mar 27.

Coagulation of cerebrospinal fluid--the Nonne-Froin sign.
Mattsson N, Montelius R, Holtz A, Mouwitz L, Blennow K, Zetterberg H.
Pract Neurol. 2013 Aug 13

Idiopathic normal-pressure hydrocephalus: pathophysiology and diagnosis by CSF biomarkers.
Jeppsson A, Zetterberg H, Blennow K, Wikkelsø C.
Neurology. 2013 Apr 9. Epub 2013 Mar 13.

Soluble Amyloid Precursor Protein α and β in CSF in Alzheimer's Disease.
Brinkmalm G, Brinkmalm A, Bourgeois P, Persson R, Hansson O, Portelius E, Mercken M, Andreasson U, Parent S, Lipari F, Ohrfelt A, Bjerke M, Minthon L, Zetterberg H, Blennow K, Nutu M. Brain Res. 2013 Mar 26 [Epub ahead of print]

Coagulation of cerebrospinal fluid--the Nonne-Froin sign.
Mattsson N, Montelius R, Holtz A, Mouwitz L, Blennow K, Zetterberg H. Pract Neurol. 2013 Mar 13. [Epub ahead of print] No abstract available.

Idiopathic normal-pressure hydrocephalus: Pathophysiology and diagnosis by CSF biomarkers.
Jeppsson A, Zetterberg H, Blennow K, Wikkelsø C. Neurology. 2013 Mar 13. [Epub ahead of print]

Serum but not cerebrospinal fluid levels of insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3) are increased in Alzheimer's disease.
Johansson P, Aberg D, Johansson JO, Mattsson N, Hansson O, Ahrén B, Isgaard J, Aberg ND, Blennow K, Zetterberg H, Wallin A, Svensson J. Psychoneuroendocrinology. 2013 Mar 6. [Epub ahead of print]
PMID: 23473966 [PubMed - as supplied by publisher]

Olympic boxing is associated with elevated levels of the neuronal protein tau in plasma.
Neselius S, Zetterberg H, Blennow K, Randall J, Wilson D, Marcusson J, Brisby H. Brain Inj. Epub 2013 Mar 8.

Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infections.
Grahn A, Hagberg L, Nilsson S, Blennow K, Zetterberg H, Studahl M.
J Neurol. 2013 Mar 8. [Epub ahead of print]


CSF biomarkers for Alzheimer's pathology and the effect size of APOE ɛ4.
Andreasson U, Lautner R, Schott JM, Mattsson N, Hansson O, Herukka SK, Helisalmi S, Ewers M, Hampel H, Wallin A, Minthon L, Hardy J, Blennow K, Zetterberg H. Mol Psychiatry. 2013 Feb 19. [Epub ahead of print] No abstract available.

Decreased cerebrospinal fluid secretogranin II concentrations in severe forms of bipolar disorder.
Jakobsson J, Stridsberg M, Zetterberg H, Blennow K, Ekman CJ, Johansson AG, Sellgren C, Landén M. J Psychiatry Neurosci. 2012 Feb 19;38(1):120170. doi: 10.1503/jpn.120170. [Epub ahead of print]

Biomarkers of mild traumatic brain injury in cerebrospinal fluid and blood.
Zetterberg H, Smith DH, Blennow K. Nat Rev Neurol. 2013 Feb 12. [Epub ahead of print]

Plasma Amyloid-β in Patients with Tangier Disease.
Shahim P, Bochem AE, Mattsson N, Lautner R, Blennow K, Hovingh GK, Motazacker MM, Zetterberg H. J Alzheimers Dis. 2013 Feb 6. [Epub ahead of print]

Alzheimer disease biomarker testing in cerebrospinal fluid: a method to harmonize assay platforms in the absence of an absolute reference standard.
Vanderstichele HM, Shaw L, Vandijck M, Jeromin A, Zetterberg H, Blennow K, Teunissen C, Engelborghs S.
Clin Chem. Epub 2013 Jan 25. No abstract available.
 

 Complement Gene Single Nucleotide Polymorphisms and Biomarker Endophenotypes of Alzheimer's Disease.
Daborg J, Holmgren S, Abramsson A, Andreasson U, Zetterberg M, Nilsson S, Minthon L, Skoog I, Blennow K, Pekna M, Hanse E, Zetterberg H. J Alzheimers Dis. 2013 Jan 11. [Epub ahead of print]


Cerebrospinal fluid CXCL13 in Lyme neuroborreliosis and asymptomatic HIV infection.
Bremell D, Mattsson N, Edsbagge M, Blennow K, Andreasson U, Wikkelsö C, Zetterberg H, Hagberg L. BMC Neurol. 2013 Jan 7;13(1):2. [Epub ahead of print]

2012

Publikationer från 2012 med länkar till abstrakt i pubmed.

Unimpaired postprandial pancreatic polypeptide secretion in Parkinson's disease and REM sleep behavior disorder.
Unger MM, Ekman R, Björklund AK, Karlsson G, Andersson C, Mankel K, Bohne K, Tebbe JJ, Stiasny-Kolster K, Möller JC, Mayer G, Kann PH, Oertel WH. Mov Disord. 2012 Dec 12. doi: 10.1002/mds.25246. [Epub ahead of print]

Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium.
Carrillo MC, Blennow K, Soares H, Lewczuk P, Mattsson N, Oberoi P, Umek R, Vandijck M, Salamone S, Bittner T, Shaw LM, Stephenson D, Bain L, Zetterberg H. Alzheimers Dement. 2012 Dec 28. doi:pii: S1552-5260(12)02521-6. 10.1016/j.jalz.2012.11.003. [Epub ahead of print]

 

Cerebrospinal Fluid Levels of Heart Fatty Acid Binding Protein are Elevated Prodromally in Alzheimer's Disease and Vascular Dementia.
Olsson B, Hertze J, Ohlsson M, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, Zetterberg H, Blennow K, Hansson O. J Alzheimers Dis. 2012 Dec 19. [Epub ahead of print]

Aβ1-15/16 as a Potential Diagnostic Marker in Neurodegenerative Diseases.
Nutu M, Bourgeois P, Zetterberg H, Portelius E, Andreasson U, Parent S, Lipari F, Hall S, Constantinescu R, Hansson O, Blennow K. Neuromolecular Med. 2012 Dec 7.


The neuropathology and neurobiology of traumatic brain injury.
Blennow K, Hardy J, Zetterberg H.Neuron. 2012 Dec 6;76(5):886-99. doi: 10.1016/j.neuron.2012.11.021.


Altered Concentrations of Amyloid Precursor Protein Metabolites in the Cerebrospinal Fluid of Patients with Bipolar Disorder.
Jakobsson J, Zetterberg H, Blennow K, Johan Ekman C, Johansson AG, Landén M. Neuropsychopharmacology. 2012 Nov 6. doi: 10.1038/npp.2012.231. [Epub ahead of print]

Biomarker evidence for uncoupling of amyloid build-up and toxicity in Alzheimer's disease.
Zetterberg H, Blennow K. Alzheimers Dement. 2012 Nov 14. doi:pii: S1552-5260(12)02392-8. 10.1016/j.jalz.2012.07.002. [Epub ahead of print]

Reduced cerebrospinal fluid level of thyroxine in patients with Alzheimer's disease.
Johansson P, Almqvist EG, Johansson JO, Mattsson N, Hansson O, Wallin A, Blennow K, Zetterberg H, Svensson J. Psychoneuroendocrinology. 2012 Nov 14. doi:pii: S0306-4530(12)00347-2. 10.1016/j.psyneuen.2012.10.012. [Epub ahead of print]

Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease.
Alves G, Pedersen KF, Bloem BR, Blennow K, Zetterberg H, Borm GF, Dalaker TO, Beyer MK, Aarsland D, Andreasson U, Lange J, Tysnes OB, Zivadinov R, Larsen JP. J Neurol Neurosurg Psychiatry. 2012 Oct 31. [Epub ahead of print]

 

Changes in serum and cerebrospinal fluid cytokines in response to non-neurological surgery: an observational study.
Bromander S, Anckarsäter R, Kristiansson M, Blennow K, Zetterberg H, Anckarsäter H, Wass CE. J Neuroinflammation. 2012 Oct 24;9(1):242. [Epub ahead of print]

A Selected Reaction Monitoring (SRM)-Based Method for Absolute Quantification of Aβ38, Aβ40, and Aβ42 in Cerebrospinal Fluid of Alzheimer's Disease Patients and Healthy Controls.
Pannee J, Portelius E, Oppermann M, Atkins A, Hornshaw M, Zegers I, Höjrup P, Minthon L, Hansson O, Zetterberg H, Blennow K, Gobom J. J Alzheimers Dis. 2012 Oct 17. [Epub ahead of print]


Cerebrospinal fluid biomarkers of β-amyloid metabolism in multiple sclerosis.
Augutis K, Axelsson M, Portelius E, Brinkmalm G, Andreasson U, Gustavsson MK, Malmeström C, Lycke J, Blennow K, Zetterberg H, Mattsson N. Mult Scler. 2012 Oct 15. [Epub ahead of print]

Cerebrospinal fluid Alzheimer's biomarker profiles in CNS infections.
Krut JJ, Zetterberg H, Blennow K, Cinque P, Hagberg L, Price RW, Studahl M, Gisslén M. J Neurol. 2012 Oct 9. [Epub ahead of print]

Serum levels of LIGHT in MS.
Malmeström C, Gillett A, Jernås M, Khademi M, Axelsson M, Kockum I, Mattsson N, Zetterberg H, Blennow K, Alfredsson L, Wadenvik H, Lycke J, Olsson T, Olsson B. Mult Scler. 2012 Oct 4. [Epub ahead of print]

Open-heart surgery increases cerebrospinal fluid levels of Alzheimer-associated amyloid β.
Reinsfelt B, Westerlind A, Blennow K, Zetterberg H, Ricksten SE. Acta Anaesthesiol Scand. 2013 Jan;57(1):82-8. doi: 10.1111/j.1399-6576.2012.02769.x. Epub 2012 Sep 24.
 


Fluid biomarkers in Alzheimer disease.
Blennow K, Zetterberg H, Fagan AM.
Cold Spring Harb Perspect Med. 2012 Sep 


Amyloid-β metabolism in Niemann-Pick C disease models and patients.
Mattsson N, Olsson M, Gustavsson MK, Kosicek M, Malnar M, Månsson JE, Blomqvist M, Gobom J, Andreasson U, Brinkmalm G, Vite C, Hecimovic S, Hastings C, Blennow K, Zetterberg H, Portelius E.
Metab Brain Dis. 2012 Sep 1. [Epub ahead of print]

 

Accuracy of a Panel of 5 Cerebrospinal Fluid Biomarkers in the Differential Diagnosis of Patients With Dementia and/or Parkinsonian Disorders.
Hall S, Ohrfelt A, Constantinescu R, Andreasson U, Surova Y, Bostrom F, Nilsson C, Widner H, Decraemer H, Nägga K, Minthon L, Londos E, Vanmechelen E, Holmberg B, Zetterberg H, Blennow K, Hansson O.
Arch Neurol. 2012 Aug 27:1-8. 


Low Cerebrospinal Fluid Sulfatide Predicts Progression of White Matter Lesions - The LADIS Study.
Jonsson M, Zetterberg H, Rolstad S, Edman A, Gouw AA, Bjerke M, Lind K, Blennow K, Pantoni L, Inzitari D, Wallin A.
Dement Geriatr Cogn Disord. 2012;34(1):61-7. Epub 2012 Aug 22.


Reference measurement procedures for Alzheimer's disease cerebrospinal fluid biomarkers: definitions and approaches with focus on amyloid β42.
Mattsson N, Zegers I, Andreasson U, Bjerke M, Blankenstein MA, Bowser R, Carrillo MC, Gobom J, Heath T, Jenkins R, Jeromin A, Kaplow J, Kidd D, Laterza OF, Lockhart A, Lunn MP, Martone RL, Mills K, Pannee J, Ratcliffe M, Shaw LM, Simon AJ, Soares H, Teunissen CE, Verbeek MM, Umek RM, Vanderstichele H, Zetterberg H, Blennow K, Portelius E.
Biomark Med. 2012 Aug;6(4):409-17.

 

Proficiency testing programs for Alzheimer's disease cerebrospinal fluid biomarkers.
Mattsson N, Andreasson U, Carrillo MC, Persson S, Shaw LM, Zegers I, Zetterberg H, Blennow K.
Biomark Med. 2012 Aug;6(4):401-7.
 


Determining cut-points for Alzheimer's disease biomarkers: statistical issues, methods and challenges.
Bartlett JW, Frost C, Mattsson N, Skillbäck T, Blennow K, Zetterberg H, Schott JM.
Biomark Med. 2012 Aug;6(4):391-400.
 


MS risk genes are transcriptionally regulated in CSF leukocytes at relapse.
Jernås M, Malmeström C, Axelsson M, Olsson C, Nookaew I, Wadenvik H, Zetterberg H, Blennow K, Lycke J, Rudemo M, Olsson B.
Mult Scler. 2012 Aug 20. [Epub ahead of print]
 


Microglial Markers are Elevated in the Prodromal Phase of Alzheimer's Disease and Vascular Dementia.
Olsson B, Hertze J, Lautner R, Zetterberg H, Nägga K, Höglund K, Basun H, Annas P, Lannfelt L, Andreasen N, Minthon L, Blennow K, Hansson O. J Alzheimers Dis. 2012 Aug 13. [Epub ahead of print]
 


Mass Spectrometric Characterization of Amyloid-β Species in the 7PA2 Cell Model of Alzheimer's Disease.
Portelius E, Olsson M, Brinkmalm G, Rüetschi U, Mattsson N, Andreasson U, Gobom J, Brinkmalm A, Hölttä M, Blennow K, Zetterberg H. J Alzheimers Dis. 2012 Aug 10. [Epub ahead of print]
 


Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study.
Randall J, Mörtberg E, Provuncher GK, Fournier DR, Duffy DC, Rubertsson S, Blennow K, Zetterberg H, Wilson DH.
Resuscitation. 2012 Aug 9. [Epub ahead of print]
 


Peptidome Analysis of Cerebrospinal Fluid by LC-MALDI MS.
Hölttä M, Zetterberg H, Mirgorodskaya E, Mattsson N, Blennow K, Gobom J. PLoS One. 2012;7(8):e42555. Epub 2012 Aug 6.
 


Development and assessment of sensitive immuno-PCR assays for the quantification of cerebrospinal fluid three- and four-repeat tau isoforms in tauopathies.
Luk C, Compta Y, Magdalinou N, Martí MJ, Hondhamuni G, Zetterberg H, Blennow K, Constantinescu R, Pijnenburg Y, Mollenhauer B, Trenkwalder C, Van Swieten J, Chiu WZ, Borroni B, Cámara A, Cheshire P, Williams DR, Lees AJ, de Silva R. J Neurochem. 2012 Aug 6. doi: 10.1111/j.1471-4159.2012.07911.x. [Epub ahead of print]

 

Second generation γ-secretase modulators exhibit different modulation of Notch β and Aβ production.
Wanngren J, Ottervald J, Parpal S, Portelius E, Strömberg K, Borgegård T, Klintenberg R, Juréus A, Blomqvist J, Blennow K, Zetterberg H, Lundkvist J, Rosqvist S, Karlström H. J Biol Chem. 2012 Jul 31. [Epub ahead of print]
 


Extreme Stability of Chitotriosidase in Cerebrospinal Flulid makes it a Suitable Marker for Microglial Activation in Clinical Trials.
Olsson B, Malmeström C, Basun H, Annas P, Höglund K, Lannfelt L, Andreasen N, Zetterberg H, Blennow K.
J Alzheimers Dis. 2012 Jul 11. [Epub ahead of print]

 
Neuropeptide levels in Dercum's disease (adiposis dolorosa).
Hansson E, Manjer J, Svensson H, Aberg M, Fagher B, Ekman R, Brorson H. Reumatismo. 2012 Jul 19;64(3):134-41.

 

Plasma BDNF levels vary in relation to body weight in females.
Pillai A, Bruno D, Sarreal AS, Hernando RT, Saint-Louis LA, Nierenberg J, Ginsberg SD, Pomara N, Mehta PD, Zetterberg H, Blennow K, Buckley PF. PLoS One. 2012;7(7):e39358. Epub 2012 Jul 2.

 

Lower CSF amyloid beta peptides and higher F2-isoprostanes in cognitively intact elderly individuals with major depressive disorder.
Pomara N, Bruno D, Sarreal AS, Hernando RT, Nierenberg J, Petkova E, Sidtis JJ, Wisniewski TM, Mehta PD, Pratico D, Zetterberg H, Blennow K. Am J Psychiatry. 2012 May;169(5):523-30.

 

Comparison of Brief Cognitive Tests and CSF Biomarkers in Predicting Alzheimer's Disease in Mild Cognitive Impairment: Six-Year Follow-Up Study.
Palmqvist S, Hertze J, Minthon L, Wattmo C, Zetterberg H, Blennow K, Londos E, Hansson O. PLoS One. 2012;7(6):e38639. Epub 2012 Jun 22.
 


CSF Biomarkers Correlate with Cerebral Blood Flow on SPECT in Healthy Elderly.
Stomrud E, Forsberg A, Hägerström D, Ryding E, Blennow K, Zetterberg H, Minthon L, Hansson O, Londos E.
Dement Geriatr Cogn Disord. 2012;33(2-3):156-63. Epub 2012 May 7.

 

Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: More to Come?
Zetterberg H, Blennow K. J Alzheimers Dis. 2012 Jun 18. [Epub ahead of print]
 


CSF T-Tau/Aβ42 predicts white matter microstructure in healthy adults at risk for Alzheimer's disease.
Bendlin BB, Carlsson CM, Johnson SC, Zetterberg H, Blennow K, Willette AA, Okonkwo OC, Sodhi A, Ries ML, Birdsill AC, Alexander AL, Rowley HA, Puglielli L, Asthana S, Sager MA.PLoS One. 2012;7(6):e37720. Epub 2012 Jun 6.

 

Cerebrospinal fluid markers of brain injury, inflammation, and blood-brain barrier dysfunction in cardiac surgery.
Reinsfelt B, Ricksten SE, Zetterberg H, Blennow K, Fredén-Lindqvist J, Westerlind A. Ann Thorac Surg. 2012 Aug;94(2):549-55. Epub 2012 Jun 13.

 

A novel ARC gene polymorphism is associated with reduced risk of Alzheimer's disease.
Landgren S, von Otter M, Palmér MS, Zetterström C, Nilsson S, Skoog I, Gustafson DR, Minthon L, Wallin A, Andreasen N, Bogdanovic N, Marcusson J, Blennow K, Zetterberg H, Kettunen P. J Neural Transm. 2012 Jul;119(7):833-42. Epub 2012 May 25.

 

An online nano-LC-ESI-FTICR-MS method for comprehensive characterization of endogenous fragments from amyloid β and amyloid precursor protein in human and cat cerebrospinal fluid.
Brinkmalm G, Portelius E, Öhrfelt A, Mattsson N, Persson R, Gustavsson MK, Vite CH, Gobom J, Månsson JE, Nilsson J, Halim A, Larson G, Rüetschi U, Zetterberg H, Blennow K, Brinkmalm A. J Mass Spectrom. 2012 May;47(5):591-603. doi: 10.1002/jms.2987.
 

Monte Carlo feature selection and rule-based models to predict Alzheimer's disease in mild cognitive impairment.
Kruczyk M, Zetterberg H, Hansson O, Rolstad S, Minthon L, Wallin A, Blennow K, Komorowski J, Andersson MG. J Neural Transm. 2012 Jul;119(7):821-31. Epub 2012 May 10.
 

Amyloid-β1-15/16 as a Marker for γ-Secretase Inhibition in Alzheimer's Disease.
Portelius E, Zetterberg H, Dean RA, Marcil A, Bourgeois P, Nutu M, Andreasson U, Siemers E, Mawuenyega KG, Sigurdson WC, May PC, Paul SM, Holtzman DM, Blennow K, Bateman RJ. J Alzheimers Dis. 2012 Jan 1;31(2):335-41.
 

CSF-Biomarkers in Olympic Boxing: Diagnosis and Effects of Repetitive Head Trauma.
Neselius S, Brisby H, Theodorsson A, Blennow K, Zetterberg H, Marcusson J. PLoS One. 2012;7(4):e33606. Epub 2012 Apr 4.

 

Cerebrospinal fluid levels of complement proteins C3, C4 and CR1 in Alzheimer's disease.
Daborg J, Andreasson U, Pekna M, Lautner R, Hanse E, Minthon L, Blennow K, Hansson O, Zetterberg H. J Neural Transm. 2012 Apr 10. [Epub ahead of print]

 

Longitudinal Cerebrospinal Fluid Biomarkers over Four Years in Mild Cognitive Impairment.
Mattsson N, Portelius E, Rolstad S, Gustavsson M, Andreasson U, Stridsberg M, Wallin A, Blennow K, Zetterberg H. J Alzheimers Dis. 2012 Apr 4. [Epub ahead of print]

 

Effect of Immunotherapy With Bapineuzumab on Cerebrospinal Fluid Biomarker Levels in Patients With Mild to Moderate Alzheimer Disease.
Blennow K, Zetterberg H, Rinne JO, Salloway S, Wei J, Black R, Grundman M, Liu E; for the AAB-001 201/202 Investigators.
Arch Neurol. 2012 Apr 2. [Epub ahead of print]

 

Lower CSF Amyloid Beta Peptides and Higher F2-Isoprostanes in Cognitively Intact Elderly Individuals With Major Depressive Disorder.
Pomara N, Bruno D, Sarreal AS, Hernando RT, Nierenberg J, Petkova E, Sidtis JJ, Wisniewski TM, Mehta PD, Pratico D, Zetterberg H, Blennow K. Am J Psychiatry. 2012 Mar 28. [Epub ahead of print]

 

Multiplexing and multivariate analysis in neurodegeneration.
Andreasson U, Portelius E, Pannee J, Zetterberg H, Blennow K.
Methods. 2012 Feb 25. [Epub ahead of print]
 

Cerebrospinal fluid profiles of amyloid β-related biomarkers in Alzheimer's disease.
Rosén C, Andreasson U, Mattsson N, Marcusson J, Minthon L, Andreasen N, Blennow K, Zetterberg H.
Neuromolecular Med. 2012 Mar;14(1):65-73. Epub 2012 Feb 18.


 

BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system.
Mattsson N, Rajendran L, Zetterberg H, Gustavsson M, Andreasson U, Olsson M, Brinkmalm G, Lundkvist J, Jacobson LH, Perrot L, Neumann U, Borghys H, Mercken M, Dhuyvetter D, Jeppsson F, Blennow K, Portelius E.
PLoS One. 2012;7(2):e31084. Epub 2012 Feb 6.

 

The amyloid-β isoform pattern in cerebrospinal fluid in familial PSEN1 M139T- and L286P-associated Alzheimer's disease.
Portelius E, Fortea J, Molinuevo JL, Gustavsson MK, Andreasson U, Sanchez-Valle R. Mol Med Report. 2012 Feb 1. doi: 10.3892/mmr.2012.774. [Epub ahead of print]
 

Age and diagnostic performance of Alzheimer disease CSF biomarkers.
Mattsson N, Rosén E, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek MM, Olde Rikkert M, Tsolaki M, Mulugeta E, Aarsland D, Visser PJ, Schröder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Wallin A, Eriksdotter-Jönhagen M, Minthon L, Winblad B, Blennow K, Zetterberg H. Neurology. 2012 Feb 1. 


Evaluation of the Performance of Novel Aβ Isoforms as Theragnostic Markers in Alzheimer's Disease: From the Cell to the Patient.
Portelius E, Gustavsson MK, Zetterberg H, Andreasson U, Blennow K.
Neurodegener Dis. 2012 Feb 1. [Epub ahead of print]
 

 Pyroglutamate A(beta) aggravates behavioral deficits in 5XFAD mice.
Wittnam JL, Portelius E, Zetterberg H, Gustavsson MK, Schilling S, Koch B, Demuth HU, Blennow K, Wirths O, Bayer TA.
J Biol Chem. 2012 Jan 20. [Epub ahead of print]

Cerebrospinal Fluid Levels of β-Amyloid 1-42, but Not of Tau, Are Fully Changed Already 5 to 10 Years Before the Onset of Alzheimer Dementia.
Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O. Arch Gen Psychiatry. 2012 Jan;69(1):98-106.

2011

Publikationer från 2011 med länkar till abstrakt i pubmed.

Leukocyte Telomere Length (LTL) is reduced in stable mild cognitive impairment but low LTL is not associated with conversion to Alzheimer's Disease: A pilot study.
Movérare-Skrtic S, Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Zetterberg H, Blennow K, Svensson J. Exp Gerontol. 2011 Dec 22. [Epub ahead of print]

Hypoxia Due to Cardiac Arrest Induces a Time-Dependent Increase in Serum Amyloid β Levels in Humans.
Zetterberg H, Mörtberg E, Song L, Chang L, Provuncher GK, Patel PP, Ferrell E, Fournier DR, Kan CW, Campbell TG, Meyer R, Rivnak AJ, Pink BA, Minnehan KA, Piech T, Rissin DM, Duffy DC, Rubertsson S, Wilson DH, Blennow K. PLoS One. 2011;6(12):e28263. Epub 2011 Dec 14.

Biomarkers for microglial activation in Alzheimer's disease.
Lautner R, Mattsson N, Schöll M, Augutis K, Blennow K, Olsson B, Zetterberg H.Int J Alzheimers Dis. 2011;2011:939426. Epub 2011 Nov 1.

Plasma tau protein in comatose patients after cardiac arrest treated with therapeutic hypothermia.
Mörtberg E, Zetterberg H, Nordmark J, Blennow K, Catry C, Decraemer H, Vanmechelen E, Rubertsson S.
Acta Anaesthesiol Scand. 2011 Oct.

Progression from Mild to Pronounced MCI Is Not Associated with Cerebrospinal Fluid Biomarker Deviations.
Wallin A, Göthlin M, Gustavsson M, Zetterberg H, Eckerström C, Blennow K, Edman A, Lind K, Nordlund A, Rolstad S. Dement Geriatr Cogn Disord. 2011 Nov 3;32(3):193-197. [Epub ahead of print]

Measurement of Aβ1-42 in cerebrospinal fluid is influenced by matrix effects.
Slemmon JR, Meredith J, Guss V, Andreasson U, Andreasen N, Zetterberg H, Blennow K. J Neurochem. 2011 Oct 25. doi: 10.1111/j.1471-4159.2011.07553.x. [Epub ahead of print]

Urate as a marker of development and progression in Parkinson's disease.
Constantinescu R, Zetterberg H. Drugs Today (Barc). 2011 May

Amyloid-β associated volume loss occurs only in the presence of phospho-tau.
Desikan RS, McEvoy LK, Thompson WK, Holland D, Roddey JC, Blennow K, Aisen PS, Brewer JB, Hyman BT, Dale AM. Ann Neurol. 2011 Oct

Predicting MCI outcome with clinically available MRI and CSF biomarkers.
Heister D, Brewer JB, Magda S, Blennow K, McEvoy LK; For the Alzheimer's Disease Neuroimaging Initiative.Neurology. 2011 Oct 25

 Levels of cerebrospinal fluid neurofilament light protein in healthy elderly vary as a function of TOMM40 variants.
Bruno D, Pomara N, Nierenberg JJ, Ritchie JC, Lutz MW, Zetterberg H, Blennow K. Exp Gerontol. 2011 Oct 1. [Epub ahead of print]

Elevated CSF levels of TACE activity and soluble TNF receptors in subjects with mild cognitive impairment and patients with Alzheimer's disease.
Jiang H, Hampel H, Prvulovic D, Wallin A, Blennow K, Li R, Shen Y. Mol Neurodegener. 2011 Oct 6

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates.
Mulugeta E, Londos E, Hansson O, Ballard C, Skogseth R, Minthon L, Blennow K, Zetterberg H, Aarsland D. Int J Alzheimers Dis. 2011;2011:495025. Epub 2011 Sep 28.

Evaluation of Plasma Aβ as Predictor of Alzheimer's Disease in Older Individuals Without Dementia: A Population-Based Study.
Hansson O, Stomrud E, Vanmechelen E, Ostling S, Gustafson DR, Zetterberg H, Blennow K, Skoog I. J Alzheimers Dis. 2011 Sep 28. [Epub ahead of print]

New diagnostic criteria for Alzheimer's disease.
Zetterberg H. Biomark Med. 2011 Aug

Identification of Novel α-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method.
Ohrfelt A, Zetterberg H, Andersson K, Persson R, Secic D, Brinkmalm G, Wallin A, Mulugeta E, Francis PT, Vanmechelen E, Aarsland D, Ballard C, Blennow K, Westman-Brinkmalm A. Neurochem Res. 2011 Nov;36(11):2029-42. Epub 2011 Jun 16.

SILAC zebrafish for quantitative analysis of protein turnover and tissue regeneration.
Westman-Brinkmalm A, Abramsson A, Pannee J, Gang C, Gustavsson MK, von Otter M, Blennow K, Brinkmalm G, Heumann H, Zetterberg H. J Proteomics. 2011 Aug 18. [Epub ahead of print]

Amyloid-related biomarkers and axonal damage proteins in parkinsonian syndromes.
Bech S, Hjermind LE, Salvesen L, Nielsen JE, Heegaard NH, Jørgensen HL, Rosengren L, Blennow K, Zetterberg H, Winge K. Parkinsonism Relat Disord. 2011 Aug 26. [Epub ahead of print] 

Cerebrospinal Fluid Matrix Metalloproteinases and Tissue Inhibitor of Metalloproteinases in Combination with Subcortical and Cortical Biomarkers in Vascular Dementia and Alzheimer's Disease.
Bjerke M, Zetterberg H, Edman A, Blennow K, Wallin A, Andreasson U.
J Alzheimers Dis. 2011 Aug 22. [Epub ahead of print]

 The N-terminal domain of α-dystroglycan is released as a 38kDa protein and is increased in cerebrospinal fluid in patients with Lyme neuroborreliosis.
Hesse C, Johansson I, Mattsson N, Bremell D, Andreasson U, Halim A, Anckarsäter R, Blennow K, Anckarsäter H, Zetterberg H, Larson G, Hagberg L, Grahn A. Biochem Biophys Res Commun. 2011 Aug 6. [Epub ahead of print]

Neuroendocrine Assessment of Serotonergic, Dopaminergic, and Noradrenergic Functions in Alcohol-Dependent Individuals.
Fahlke C, Berggren U, Berglund KJ, Zetterberg H, Blennow K, Engel JA, Balldin J. Alcohol Clin Exp Res. 2011 Jul 28. [Epub ahead of print] 

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers.
Mattsson N, Andreasson U, Persson S, Arai H, Batish SD, Bernardini S, Bocchio-Chiavetto L, Blankenstein MA, Carrillo MC, Chalbot S, Coart E, Chiasserini D, Cutler N, Dahlfors G, Duller S, Fagan AM, Forlenza O, Frisoni GB, Galasko D, Galimberti D, Hampel H, Handberg A, Heneka MT, Herskovits AZ, Herukka SK, Holtzman DM, Humpel C, Hyman BT, Iqbal K, Jucker M, Kaeser SA, Kaiser E, Kapaki E, Kidd D, Klivenyi P, Knudsen CS, Kummer MP, Lui J, Lladó A, Lewczuk P, Li QX, Martins R, Masters C, McAuliffe J, Mercken M, Moghekar A, Molinuevo JL, Montine TJ, Nowatzke W, O'Brien R, Otto M, Paraskevas GP, Parnetti L, Petersen RC, Prvulovic D, de Reus HP, Rissman RA, Scarpini E, Stefani A, Soininen H, Schröder J, Shaw LM, Skinningsrud A, Skrogstad B, Spreer A, Talib L, Teunissen C, Trojanowski JQ, Tumani H, Umek RM, Van Broeck B, Vanderstichele H, Vecsei L, Verbeek MM, Windisch M, Zhang J, Zetterberg H, Blennow K. Alzheimers Dement. 2011 Jul;7(4):386-395.e6. 

Novel Aβ Isoforms in Alzheimer´s Disease - Their Role in Diagnosis and Treatment.
Portelius E, Mattsson N, Andreasson U, Blennow K, Zetterberg H. Curr Pharm Des. 2011 Jul 5. [Epub ahead of print] 

Site-specific characterization of threonine, serine, and tyrosine glycosylations of amyloid precursor protein/amyloid {beta}-peptides in human cerebrospinal fluid.
Halim A, Brinkmalm G, Rüetschi U, Westman-Brinkmalm A, Portelius E, Zetterberg H, Blennow K, Larson G, Nilsson J. Proc Natl Acad Sci U S A. 2011 Jul 19;108(29):11848-53. Epub 2011 Jun 28.

Central Nervous System Lipocalin-Type Prostaglandin D2-Synthase is Correlated with Orexigenic Neuropeptides, Visceral Adiposity and Markers of the Hypothalamic-Pituitary-Adrenal Axis in Obese Humans.
Elias E, Benrick A, Behre CJ, Ekman R, Zetterberg H, Stenlöf K, Wallenius V. J Neuroendocrinol. 2011 Jun;23(6):501-507.

Identification of Novel α-Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method.
Ohrfelt A, Zetterberg H, Andersson K, Persson R, Secic D, Brinkmalm G, Wallin A, Mulugeta E, Francis PT, Vanmechelen E, Aarsland D, Ballard C, Blennow K, Westman-Brinkmalm A.Neurochem Res. 2011 Jun 16. [Epub ahead of print]

Do Alcohol-dependent Individuals with DRD2 A1 Allele Have an Increased Risk of Relapse? A Pilot Study.
Dahlgren A, Wargelius HL, Berglund KJ, Fahlke C, Blennow K, Zetterberg H, Oreland L, Berggren U, Balldin J. Alcohol Alcohol. 2011 May 25. [Epub ahead of print]

Reward-Related Genes and Personality Traits in Alcohol-Dependent Individuals: A Pilot Case Control Study.
Landgren S, Berglund K, Jerlhag E, Fahlke C, Balldin J, Berggren U, Zetterberg H, Blennow K, Engel JA. Neuropsychobiology. 2011 May 24;64(1):38-46. [Epub ahead of print]

Amyloid-β42 is Associated with Cognitive Impairment in Healthy Elderly and Subjective Cognitive Impairment.
Rolstad S, Berg AI, Bjerke M, Blennow K, Johansson B, Zetterberg H, Wallin A.

Cerebrospinal fluid microglial markers in Alzheimer's disease: elevated chitotriosidase activity but lack of diagnostic utility.
Mattsson N, Tabatabaei S, Johansson P, Hansson O, Andreasson U, Månsson JE, Johansson JO, Olsson B, Wallin A, Svensson J, Blennow K, Zetterberg H. Neuromolecular Med. 2011 Jun;13(2):151-9. Epub 2011 May 13.

No Association of LOXL1 Gene Polymorphisms with Alzheimer's Disease.
Abramsson A, Landgren S, Zetterberg M, Seibt Palmer M, Minthon L, Gustafson DR, Skoog I, Blennow K, Zetterberg H.

Alzheimer's disease markers, hypertension, and gray matter damage in normal elderly.
Glodzik L, Mosconi L, Tsui W, de Santi S, Zinkowski R, Pirraglia E, Rich KE, McHugh P, Li Y, Williams S, Ali F, Zetterberg H, Blennow K, Mehta P, de Leon MJ. Neurobiol Aging. 2011 Apr 27. [Epub ahead of print]

Biomarker-based dissection of neurodegenerative diseases.
Olsson B, Zetterberg H, Hampel H, Blennow K. Prog Neurobiol. 2011 Apr 16. [Epub ahead of print]

Mild dementia is associated with increased adrenal secretion of cortisol and precursor sex steroids in women.
Johansson P, Johansson JO, Labrie F, Mattsson N, Hansson O, Blennow K, Zetterberg H, Wallin A, Ohlsson C, Svensson J. Clin Endocrinol (Oxf). 2011 Apr 22. [Epub ahead of print]

Blood-Cerebrospinal Fluid Barrier Permeability in Alzheimer's Disease.
Chalbot S, Zetterberg H, Blennow K, Fladby T, Andreasen N, Grundke-Iqbal I, Iqbal K. J Alzheimers Dis. 2011 Apr 6. [Epub ahead of print]

Antihypertensive Therapy Is Associated with Reduced Rate of Conversion to Alzheimer's Disease in Midregional Proatrial Natriuretic Peptide Stratified Subjects with Mild Cognitive Impairment.
Schneider P, Buerger K, Teipel S, Uspenskaya O, Hartmann O, Hansson O, Minthon L, Rujescu D, Moeller HJ, Zetterberg H, Blennow K, Ernst A, Bergmann A, Hampel H. Biol Psychiatry. 2011 Mar 30. [Epub ahead of print]

Discriminatory Analysis of Biochip-Derived Protein Patterns in CSF and Plasma in Neurodegenerative Diseases.
Rosén C, Mattsson N, Johansson PM, Andreasson U, Wallin A, Hansson O, Johansson JO, Lamont J, Svensson J, Blennow K, Zetterberg H. Front Aging Neurosci. 2011 Jan 31;3:1. 

TOMM40 poly-T Variants and Cerebrospinal Fluid Amyloid Beta Levels in the Elderly.
Pomara N, Bruno D, Nierenberg JJ, Sidtis JJ, Martiniuk FT, Mehta PD, Zetterberg H, Blennow K. Neurochem Res. 2011 Apr 1. [Epub ahead of print]

Head size may modify the impact of white matter lesions on dementia.
Skoog I, Olesen PJ, Blennow K, Palmertz B, Johnson SC, Bigler ED. Neurobiol Aging. 2011 Mar 17. [Epub ahead of print]

Expression of the gene encoding the ghrelin receptor in rats selected for differential alcohol preference.
Landgren S, Engel JA, Hyytiä P, Zetterberg H, Blennow K, Jerlhag E. Behav Brain Res. 2011 Mar 15;221(1):182-188. [Epub ahead of print]

Characterization of the Brain β-Amyloid Isoform Pattern at Different Ages of Tg2576 Mice.
Mustafiz T, Portelius E, Gustavsson MK, Hölttä M, Zetterberg H, Blennow K, Nordberg A, Unger Lithner C. Neurodegener Dis. 2011 Feb 23. [Epub ahead of print]

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.
Shaw LM, Vanderstichele H, Knapik-Czajka M, Figurski M, Coart E, Blennow K, Soares H, Simon AJ, Lewczuk P, Dean RA, Siemers E, Potter W, Lee VM, Trojanowski JQ; the Alzheimer’s Disease Neuroimaging Initiative. Acta Neuropathol. 2011 Feb 11. [Epub ahead of print]

Dementia in 2010: Paving the way for Alzheimer disease drug development.
Blennow K. Nat Rev Neurol. 2011 Feb;7(2):65-6. No abstract available.

Genetic Association of Sequence Variants Near AGER/NOTCH4 and Dementia.
Bennet AM, Reynolds CA, Eriksson UK, Hong MG, Blennow K, Gatz M, Alexeyenko A, Pedersen NL, Prince JA. J Alzheimers Dis. 2011 Feb 1. [Epub ahead of print]

Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: Diagnostic Performance in a Homogeneous Mono-Center Population.
Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U, Zetterberg H, Blennow K, Svensson J.J Alzheimers Dis. 2011 Feb 1. [Epub ahead of print]

Ubiquitin Carboxyl-Terminal Esterase L1 (UCHL1) S18Y Polymorphism In Patients With Cataracts.
Rudolph T, Sjölander A, Palmér MS, Minthon L, Wallin A, Andreasen N, Tasa G, Juronen E, Blennow K, Zetterberg H, Zetterberg M. Ophthalmic Genet. 2011 Jan 26. [Epub ahead of print]


Screening for new biomarkers for subcortical vascular dementia and Alzheimer's disease.

Ohrfelt A, Andreasson U, Simon A, Zetterberg H, Edman A, Potter W, Holder D, Devanarayan V, Seeburger J, Smith AD, Blennow K, Wallin A. Dement Geriatr Cogn Dis Extra. 2011 Jan;1(1):31-42. Epub 2011 Jan 14.
 

Sidansvarig: Staffan Persson|Sidan uppdaterades: 2017-05-31
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?